White Rock expands Mt Carrington JORC Mineral Resource

|

Published 20-NOV-2017 13:30 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

The Australian gold recovery story continues, as yet another junior gold explorer reports “positive advances in some key technical areas” from its flagship base metals project in NSW.

white rock minerals jorc resource

White Rock Minerals (ASX:WRM), a junior gold explorer based in NSW, has today reported several unexpected updates from its flagship Mt Carrington Project. Currently completing Stage 1 of its extensive PFS, WRM has now officially confirmed that it has revised the Mt Carrington Mineral Resource upwards by 62 per cent.

The company also reported that its metallurgical testwork indicates a 10 per cent improvement in the level of gold recovered from processing, which now allows WRM to raise its estimated design throughput from 800,000tpa to 1,000,000tp — a 20 per cent quantifiable increase in output compared to previous tests.

WRM sample results

WRM’s updated Mineral Resource Estimate saw raw tonnage increase by 44 per cent, gold grade improving by 10 per cent, and contained gold ounces increasing by 62 per cent.

As stated, however, this is an early stage play and investors should seek professional financial advice if considering this stock for their portfolio.

This increase will have a positive flow-on effect, resulting in an increased in-pit mineral inventory from which mine production will occur. This increase has allowed the mine production rate to be revised upwards from 800,000 tpa to 1,000,000 tpa. The ensuring 25 per cent increase in throughput rate could potentially flow through to increased annual gold production for WRM.

Earlier studies contemplated a flotation stage in the circuit, with gold recoveries around 75 per cent. The latest test work, and the deferral in installing flotation, has allowed gold recoveries to increase to around 83 per cent.

With technical work progressing on schedule, WRM’s Pre-feasibility Study is now focused on estimating relevant operating costs and re-estimating capital costs required to sustain the additional throughput rate.

According to WRM, supporting studies around the design of the tailings storage facility and water management are also advancing. It is anticipated that the PFS and Reserve Statement will be completed by the end of this year.

WRM listed on the ASX in October 2010 with the vision to explore and develop both precious and base metal projects. Its cornerstone asset is the aforementioned Mt Carrington epithermal gold-silver project in northern NSW. The Mt Carrington project has great leverage to the Australian gold and silver prices with a positive Scoping Study providing a path towards feasibility studies and development in the near term.

WRM is also exploring the Red Mountain project in Alaska. Red Mountain is a quality advanced VMS project with high grade zinc and silver in two deposits. White Rock is exploring for additional high-grade deposits that will enhance the project’s leverage to an upturn in the prices of zinc and silver.

tags

GOLD


General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X